This is very encouraging but it is pre-clinical so who knows if it will advance to human trials but could be an indicator of what may come down the line. The Tactimel trial could yield some really amazing results. That is where IMP321 will be combined with Keytruda.
The current study has shown that treatment with the combined adjuvant of poly(I:C) plus LAG-3-Ig profoundly enhances antitumor responses induced by tumor peptide vaccine and leads to complete regression of pre-established tumor in association with long-term immunological memory. Furthermore, mechanistic analyses revealed the activation of Th1-type responses and prevention of the exhausted phenotype in tumor-specific T cells by this treatment. To the best of our knowledge, our study is the first to report a great advantage in combining adjuvants poly(I:C) and LAG-3-Ig for therapeutic cancer vaccine. (Lag-3-lg is Prima's IMP321.)